Antisense oligodeoxynucleotides are well known as specific inhibitor of targeted genes expression. In this paper we demonmstrate that antisenses could be applied for investigation of the molecular mechanisms activated by oncogenes These studies may identify new targets for antisense treatments of tumors.
We describe here tha current state of progress toward gene-directed antisense-based cancer therapy targeting BCR/ABL, oncogene, primarily from the viewpoint of initial proof-of-concepts studies in animal models of human leukemias and phase I clinical investigations.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.